| | | |

Mesothelioma Histology Impacts Response to Chemotherapy

ByAlex Strauss

Response to chemotherapyResponse to chemotherapy for people with malignant mesothelioma may depend – at least in part – on the histology or subtype of their tumor.

That is the finding of a new study from a team of Spanish doctors. The doctors analyzed the cases of 189 pleural mesothelioma patients treated at their hospital between 2002 and 2020. 

Their study confirms what other studies have suggested: People with epithelioid tumors have better response to chemotherapy than those with non-epithelioid subtypes. These patients experienced both longer progression-free survival and longer overall survival. 

Systemic Treatment for Pleural Mesothelioma

The first chemotherapy drug for malignant pleural mesothelioma received FDA approval in 2004. Alimta was the only approved systemic (whole body) treatment for pleural mesothelioma until 2020. 

In 2020, the FDA approved the immunotherapy drugs Yervoy and Opdivo for some mesothelioma patients. Most patients still start treatment with Alimta and a platinum drug (usually cisplatin or carboplatin). Unfortunately, response to chemotherapy varies widely among mesothelioma patients. 

Patients who respond well may have more rounds of chemotherapy if their cancer comes back. Patients who do not have a good response may try another type of treatment or a clinical trial. 

Because mesothelioma tumors grow so quickly, the ability to predict response to chemotherapy could be life-saving.

Predicting Response to Chemotherapy 

There are three main types of mesothelioma. Doctors classify them based on where they occur in the body. 

Pleural mesothelioma tumors grow on the membrane around the lungs. Peritoneal mesothelioma affects the lining of the abdomen. Pericardial mesothelioma tumors occur on the membrane around the heart. Pleural mesothelioma is by far the most common type.

Mesothelioma tumors can be further divided by the shape of the cells themselves. This is called the tumor histology. Epithelioid cells make up about 70 percent of mesotheliomas. Sarcomatoid cells are the most resistant to treatment. Biphasic tumors contain some of each kind of cell. 

Response to chemotherapy is usually better among people with epithelioid histology. The new report bears this out. Median progression-free survival for epithelioid patients treated with chemotherapy was 4.8 months. Non-epithelioid patients had a progression-free survival of 3.6 months. 

The improved response to chemotherapy meant epithelioid patients also lived longer. 

“Median OS [overall survival] of epithelioid patients treated with first line chemotherapy was 26.7 months versus 15.0 months in non-epithelioid patients.” writes lead study author Dr. Susana Cedres, an oncologist at the Hospital Universitari Vall d’Hebron in Barcelona. “In our series, patients with non-epithelioid tumors presented worse prognosis.”

Some of the epithelioid patients had longer progression-free survival if they had Alimta and cisplatin. But there did not seem to be a connection between mesothelioma subtype and response to chemotherapy with either cisplatin or carboplatin. 

Sources:

Cedres, S, et al, “Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort”, November 1, 2021, Scientific Reports, https://www.nature.com/articles/s41598-021-00831-4

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…